



## Media Release

Planegg/Munich, Germany, April 3, 2017

### MorphoSys Nominates New Candidate for Supervisory Board

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has published its agenda for the Company's ordinary Annual General Meeting (AGM), which will take place on Wednesday, May 17, 2017.

MorphoSys's Supervisory Board has nominated Krisja Vermeylen as candidate to be elected as a new Supervisory Board member at the Company's AGM. Ms. Vermeylen will replace Karin Eastham, who has resigned from her Supervisory Board mandate for personal reasons with effect from the conclusion of the AGM 2017. Furthermore the Supervisory Board has proposed to re-elect Dr. Frank Morich, Wendy Johnson and Klaus Kühn, whose terms of office would have expired with the conclusion of the AGM 2017.

"We are delighted that with Ms. Vermeylen we can present a highly qualified candidate with extensive industry expertise for MorphoSys's Supervisory Board. Ms. Vermeylen brings to our Board significant experience in product management, marketing and commercialization of pharmaceuticals," commented Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG. "On behalf of the Company, I would like to thank Ms. Eastham for her invaluable support and contribution to MorphoSys over the last five years."

Ms. Vermeylen currently serves as Senior Vice President Corporate People & Organisation at Novo Nordisk A/S, Bagsvaerd, Denmark. Over the last 20 years, she has worked with Novo Nordisk in various management positions, including as General Manager for Belgium and Luxemburg (BeLux), France and, most recently, Germany. Before joining Novo Nordisk, Ms. Vermeylen worked for several years at Pharmacia (today Pfizer). Ms. Vermeylen is a pharmacist by training and holds a master's degree in pharmaceutical sciences from the University of Antwerp (UIA, RUCA), Belgium.

#### About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic [pipeline](#) of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit <http://www.morphosys.com>.

HuCAL<sup>®</sup>, HuCAL GOLD<sup>®</sup>, HuCAL PLATINUM<sup>®</sup>, CysDisplay<sup>®</sup>, RapMAT<sup>®</sup>, arYla<sup>®</sup>, Ylantia<sup>®</sup>, 100 billion high potentials<sup>®</sup>, Slonomics<sup>®</sup>, Lanthio Pharma<sup>®</sup> and LanthioPep<sup>®</sup> are registered trademarks of the MorphoSys Group.

*This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this*

*release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.*

**For more information, please contact:**

**MorphoSys AG**

Anke Linnartz

Head of Corporate Communications & IR

Jochen Orłowski

Associate Director Corporate Communications & IR

Alexandra Goller

Senior Manager Corporate Communications & IR

**Tel: +49 (0) 89 / 899 27-404**

**[investors@morphosys.com](mailto:investors@morphosys.com)**